Market Place
Sourcing Support
FDA Granted Priority Review to Dizal`s Sunvozertinib NDA
07 Jan 2025 //
PR NEWSWIRE
Dizal Shows Sunvozertinib Data For EGFR-Resistant Lung Cancer
11 Dec 2024 //
PR NEWSWIRE
Dizal Submits NDA for Sunvozertinib in EGFR Exon 20 NSCLC
08 Nov 2024 //
PR NEWSWIRE
Sunvozertinib Shows Efficacy In NSCLC With EGFR Exon 20 Mutations
16 Sep 2024 //
PR NEWSWIRE
Sunvozertinib`s EGFR20Ins NSCLC Study Meets Primary Endpoint
02 Jun 2024 //
PR NEWSWIRE
Dizal Sunvozertinib Egfr Exon 20: Biomarker Nsclc Mutation Treatment Analysis
24 May 2024 //
PR NEWSWIRE
Dizal`s Sunvozertinib EGFR20+ NSCLC Results at ASCO 2024
24 Apr 2024 //
PR NEWSWIRE
FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the NSCLC
07 Apr 2024 //
PR NEWSWIRE
Dizal`s Sunvozertinib Pivotal Study Results Published in The Lancet Medicine
13 Dec 2023 //
PR NEWSWIRE
Sunvozertinib Showes Potential as a First-Line Treatment for EGFR Exon 20
23 Oct 2023 //
PR NEWSWIRE
Sunvozertinib Approved in China for NSCLC With EGFR Exon 20 Insertion Mutations
23 Aug 2023 //
ONCLIVE
Introduction To The Market Overview Of API
19 Apr 2023 //
PRESS RELEASE
Dizal Announces China CDE Acceptance of New Drug Application for Sunvozertinib
10 Jan 2023 //
PR NEWSWIRE
Dizal Announces Sunvozertinib Meets Primary Endpoint in its First Pivotal Study
05 Sep 2022 //
PRNEWSWIRE
Dizal Demonstrates Clinical Update for Sunvozertinib (DZD9008) in NSCLC
05 Aug 2022 //
PRNEWSWIRE
Dizal Announces Pre-clinical and Clinical Results of Sunvozertinib
05 May 2022 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.